NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who purchased Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ:APLT) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [CONTACT FORM] The lawsuit was filed on behalf of investors who acq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Applied Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 24 ...

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024. Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., ...

LOS ANGELES, Dec. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ: APLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 3, 2024 and December 2, 2024, inclusive ...

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=117779&from=4 CLASS PERIOD: ...

NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc. Investors have until February 18, 2025, to a ...

Core Viewpoint - A class action lawsuit has been filed against Applied Therapeutics, alleging securities fraud and unlawful business practices related to the company's clinical trial issues and FDA communications [1][4]. Group 1: Class Action Details - The class action lawsuit is initiated by Pomerantz LLP, targeting Applied Therapeutics and its officers/directors [4]. - Shareholders who purchased or acquired DMC securities during the Class Period can request to be appointed as Lead Plaintiff by February 18, 2025 [5]. Group 2: FDA Communications - On December 2, 2024, Applied Therapeutics received a "warning letter" from the FDA, highlighting issues with electronic data capture and a dosing error during a clinical trial [2]. - The company plans to respond to the FDA's concerns within the allowed 15 business days [2]. Group 3: Stock Price Impact - Following the announcement of the FDA's Complete Response Letter (CRL) on November 27, 2024, Applied Therapeutics' stock price dropped by $1.64, or 16.06%, closing at $8.57 per share [6]. - Over the next three trading sessions, the stock price further declined by $0.46, or 26.29%, closing at $1.29 per share on December 5, 2024 [9]. Group 4: Company Background - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members over its 85-year history [7].

Leadership Changes - Shoshana Shendelman has stepped down as CEO of Applied Therapeutics, Inc., with Les Funtleyder appointed as Interim CEO [1][19] - John H. Johnson has been named Executive Chairman, bringing over 40 years of experience in the biopharmaceutical industry [19][23] - Les Funtleyder has been with the company since June 2016 and has served as CFO since November 2023, providing continuity in leadership [2][14] Business Updates - The company has withdrawn its Marketing Authorization Application (MAA) for govorestat for the treatment of Classic Galactosemia, citing the need for more data [4] - Following a Complete Response Letter (CRL) received in November 2024 regarding the New Drug Application (NDA) for govorestat, the company is evaluating its response and potential next steps with the FDA [12][13] - The company plans to submit an NDA for govorestat for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency after the first quarter of 2025 [13] Compensation and Incentives - The Compensation Committee approved inducement awards for Mr. Johnson, including stock options for 2,000,000 shares and restricted stock units for 1,000,000 shares, with specific vesting conditions tied to regulatory approvals [5] Company Vision and Strategy - The leadership transition is viewed as a strategic move to align with the company's priorities in developing treatments for rare diseases [10] - Mr. Funtleyder emphasized the importance of maintaining high standards of integrity and quality while focusing on the clinical pipeline [22]

Core Viewpoint - A class action securities lawsuit has been filed against Applied Therapeutics, Inc. due to alleged securities fraud affecting investors between January 3, 2024, and December 2, 2024 [1][6]. Company Summary - The lawsuit is a response to a Complete Response Letter (CRL) received by Applied Therapeutics from the FDA regarding its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [6]. - Following the announcement of the CRL on November 27, 2024, Applied Therapeutics' stock price dropped significantly from $10.21 per share to $8.57 per share, and further declined to $2.03 on November 29, 2024, and $1.75 on December 2, 2024, marking a total decline of over 80% [6]. - After the disclosure of a "warning letter" from the FDA on December 2, 2024, the stock price continued to fall, reaching $1.69 on December 3, 2024, and further declining to $1.38 on December 4, 2024, and $1.29 on December 5, 2024 [6]. Legal Context - Investors who suffered losses during the specified timeframe have until February 18, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]. - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud [6]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [7]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [7].